FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229062893> ?p ?o ?g. }

• W4229062893 abstract "Abstract BACKGROUND AND AIMS To control mineral and bone disorders in haemodialysis (HD) patients, doses of vitamin D analogues and calcimimetics are adjusted based on serum parathyroid hormone (PTH) levels. Accordingly, method-related differences in PTH results may influence the prescribed dose of those drugs and PTH-lowering treatment costs. The aim of this study was to clarify the influence of inter-method variability in PTH measurement on PTH-lowering treatment costs. METHOD We used data from 30 maintenance HD patients in our facility. The Intact-PTH measuring assay was changed from the Elecsys PTH to the Alinity Intact PTH Reagent Kit (Alinity PTH) in March 2021, following a 2-month transitional period when PTH levels were measured using both assays. We examined method-related differences in PTH levels, using the results obtained in the transitional period. Using prescription records from October to December 2020, when the Elecsys PTH assay was used, and those from March to May 2021, when assay system was fully changed to the Alinity PTH, we examined the influence of the PTH measuring method on medication cost by evaluating the monthly cost of vitamin D analogues and calcimimetics in our facility. We evaluated the mean levels of serum calcium, phosphorus and PTH in 30 patients in the corresponding period. RESULTS Inter-method variability in PTH results was evaluated using 60 specimens from 30 patients. PTH results of 60 specimens ranged from 11 to 802 pg/mL and 8.8 to 1198 pg/mL in the Elecsys PTH and in the Alinity PTH, respectively. Compared with PTH levels obtained with the Elecsys PTH, those measured with the Alinity PTH were significantly higher (P &lt; .001). On average, results obtained with the Alinity PTH were 1.58-fold higher than those provided by the Elecsys PTH. When the Elecsys PTH assay was used, the average monthly cost of vitamin D analogues and calcimimetics was €44 and €1668, respectively. After the assay was changed to the Alinity PTH, the average monthly costs were €40 for vitamin D analogues and €2471 for calcimimetics (€1 = ¥130). There were no notable changes in the mean serum levels of calcium, phosphorus and PTH throughout the study period. CONCLUSION Inter-method variability in PTH results would have an influence on the cost-effective assessment of PTH lowering therapy. Standardization of PTH measurement is required." @default.
• W4229062893 created "2022-05-08" @default.
• W4229062893 creator A5007822006 @default.
• W4229062893 creator A5034160152 @default.
• W4229062893 creator A5042314348 @default.
• W4229062893 creator A5049551716 @default.
• W4229062893 creator A5064473247 @default.
• W4229062893 creator A5075010640 @default.
• W4229062893 creator A5078057186 @default.
• W4229062893 date "2022-05-01" @default.
• W4229062893 modified "2023-09-27" @default.
• W4229062893 title "MO806: Change in Pth Measuring Method Affects the Cost of Pth-Lowering Treatment" @default.
• W4229062893 doi "https://doi.org/10.1093/ndt/gfac082.004" @default.
• W4229062893 hasPublicationYear "2022" @default.
• W4229062893 type Work @default.
• W4229062893 citedByCount "0" @default.
• W4229062893 crossrefType "journal-article" @default.
• W4229062893 hasAuthorship W4229062893A5007822006 @default.
• W4229062893 hasAuthorship W4229062893A5034160152 @default.
• W4229062893 hasAuthorship W4229062893A5042314348 @default.
• W4229062893 hasAuthorship W4229062893A5049551716 @default.
• W4229062893 hasAuthorship W4229062893A5064473247 @default.
• W4229062893 hasAuthorship W4229062893A5075010640 @default.
• W4229062893 hasAuthorship W4229062893A5078057186 @default.
• W4229062893 hasConcept C124490489 @default.
• W4229062893 hasConcept C126322002 @default.
• W4229062893 hasConcept C126894567 @default.
• W4229062893 hasConcept C134018914 @default.
• W4229062893 hasConcept C2781208988 @default.
• W4229062893 hasConcept C519063684 @default.
• W4229062893 hasConcept C71924100 @default.
• W4229062893 hasConceptScore W4229062893C124490489 @default.
• W4229062893 hasConceptScore W4229062893C126322002 @default.
• W4229062893 hasConceptScore W4229062893C126894567 @default.
• W4229062893 hasConceptScore W4229062893C134018914 @default.
• W4229062893 hasConceptScore W4229062893C2781208988 @default.
• W4229062893 hasConceptScore W4229062893C519063684 @default.
• W4229062893 hasConceptScore W4229062893C71924100 @default.
• W4229062893 hasIssue "Supplement_3" @default.
• W4229062893 hasLocation W42290628931 @default.
• W4229062893 hasOpenAccess W4229062893 @default.
• W4229062893 hasPrimaryLocation W42290628931 @default.
• W4229062893 hasRelatedWork W1968602242 @default.
• W4229062893 hasRelatedWork W1970114012 @default.
• W4229062893 hasRelatedWork W1974087872 @default.
• W4229062893 hasRelatedWork W1999545086 @default.
• W4229062893 hasRelatedWork W2064236298 @default.
• W4229062893 hasRelatedWork W2067994365 @default.
• W4229062893 hasRelatedWork W2071103727 @default.
• W4229062893 hasRelatedWork W2107762597 @default.
• W4229062893 hasRelatedWork W2130345620 @default.
• W4229062893 hasRelatedWork W4253300128 @default.
• W4229062893 hasVolume "37" @default.
• W4229062893 isParatext "false" @default.
• W4229062893 isRetracted "false" @default.
• W4229062893 workType "article" @default.